Previous Topic

Next Topic

Book Contents

Authorizing and setting approvals for drug reallocation

This procedure switches on the ability for users of IRT for this study to reallocate drugs after a transaction is complete.

Important: Drug reallocations in unblinded studies must be acknowledged by an unblinded role.

  1. Click Configurations (Configurations tab (main menu)).
  2. On the left, click General Configuration.

    For descriptions of the fields on this page, see General Configuration page.

  3. In the Allow Drug Reallocation section, select Yes.
  4. In the Acknowledge section, select when drug reallocation should be acknowledged:
    • All Reallocation Transactions–All transactions require acknowledgment.
    • No Reallocation Transactions–Drug reallocations can be edited without acknowledgment.
    • Incorrect Trial Supply Transaction (Used for Open Label Trials only)–The drug type of the drug units identified by IRT is different from the drug type of the drug units provided to the subject.
  5. Select each unblinded role that should be responsible for acknowledging drug reallocations.
  6. In the Approvals Alert Frequency textbox, type the number of days between the reminders to review an approval or an acknowledgment.

    When an approval or acknowledgment is requested, IRT sends the first alert immediately. This option sets the number of days between later reminders.

  7. Click Submit.
Send Feedback